Sculptor Capital LP bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 250,000 shares of the company's stock, valued at approximately $2,490,000. Sculptor Capital LP owned 1.12% of Oaktree Acquisition Corp. III Life Sciences as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of OACC. Shaolin Capital Management LLC acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth about $5,478,000. AQR Arbitrage LLC purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 4th quarter valued at about $19,743,000. K2 Principal Fund L.P. acquired a new position in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth approximately $1,945,000. Finally, Lighthouse Investment Partners LLC purchased a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter worth approximately $3,039,000.
Oaktree Acquisition Corp. III Life Sciences Stock Down 0.1%
NASDAQ:OACC traded down $0.01 during trading hours on Thursday, hitting $10.43. The stock had a trading volume of 69,346 shares, compared to its average volume of 102,205. The firm has a 50 day simple moving average of $10.26. Oaktree Acquisition Corp. III Life Sciences has a 1-year low of $9.95 and a 1-year high of $10.85.
About Oaktree Acquisition Corp. III Life Sciences
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Further Reading
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
